On the edge of validation--cancer protease fibroblast activation protein

Area of Science:

• Biochemistry
• Oncology
• Drug Discovery

Background:

• Fibroblast activation protein (FAP) is a prolyl peptidase enzyme implicated in various stages of tumorigenesis.
• Despite its role in cancer, the lack of FAP-selective inhibitors has hindered its validation as a therapeutic target.
• Understanding FAP's function is crucial for developing effective cancer treatments.

Purpose of the Study:

• To review recent advancements in the development of fibroblast activation protein (FAP)-selective inhibitors.
• To discuss the progress made in validating FAP as a therapeutic target for cancer treatment.
• To highlight future research directions for successful FAP-targeted cancer therapy.

Main Methods:

• Literature review of recent studies on fibroblast activation protein (FAP) inhibitors.
• Analysis of research efforts focused on validating FAP as a therapeutic target.
• Synthesis of current findings and future perspectives in FAP-targeted cancer therapy.

Main Results:

• Recent research has focused on developing selective inhibitors for fibroblast activation protein (FAP).
• Progress has been made in validating FAP's role in cancer, paving the way for targeted therapies.
• Several strategies are being explored to effectively inhibit FAP for therapeutic benefit.

Conclusions:

• Fibroblast activation protein (FAP) inhibitors represent a promising avenue for cancer therapy.
• Further development of FAP-selective inhibitors is essential for clinical translation.
• Targeting FAP holds significant potential for improving outcomes in cancer patients.